Trials / Completed
CompletedNCT00621296
Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C
Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MP-424 (Telaprevir) | Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg) |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-02-22
- Last updated
- 2026-01-06
- Results posted
- 2012-10-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00621296. Inclusion in this directory is not an endorsement.